Safety and effectiveness of transdermal electrical stimulation for central retinal artery occlusio
- Conditions
- Central retinal artery occlusion
- Registration Number
- JPRN-UMIN000036219
- Lead Sponsor
- Chiba university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Not provided
1. Patients who have a history of drug allergy to drugs (mydriatics and anesthetics eye drops) to be used during the trial period. 2. Patients with complications that have a significant affect on visual function. 3. Patients with a history of or complications of malignancy. However, patients who have a history but have not relapsed for more than 5 years can be registered. 4. Patients diagnosed and treated for dementia and mental illness. 5. Patients complicated with poor control diabetes (HbA1c (NGSP)> 10.0%). 6. Patients with uncontrollable hypertension (systolic > 180 mmHg and / or diastolic 110 mmHg). 7. Patients with liver / renal dysfunction that falls under any of the following at clinical screening. AST, ALT: more than 3 times the upper limit of (facility) standard value Serum creatinine: more than 1.5 times the upper limit of (institutional) standard value 8. Patients taking ethambutol hydrochloride and / or amiodarone hydrochloride. 9. Patients who were pregnant, breastfeeding, may be or planned to be pregnant during the trial period. 10. Patients participating in other clinical trials. 11. Patients under investigational responsibility (shared) doctors judged inappropriate for participation in this trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method logMAR visual acuity
- Secondary Outcome Measures
Name Time Method